XILIO THERAPEUTICS INC's ticker is and the CUSIP is 98422T100. A total of 32 filers reported holding XILIO THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,025,186 | -19.5% | 1,907,671 | 0.0% | 0.00% | – |
| Q2 2023 | $4,998,098 | -58.8% | 1,907,671 | -50.0% | 0.00% | -100.0% |
| Q1 2023 | $12,132,788 | +136.4% | 3,815,342 | +100.0% | 0.00% | 0.0% |
| Q4 2022 | $5,131,635 | -20.6% | 1,907,671 | -14.1% | 0.00% | 0.0% |
| Q3 2022 | $6,459,000 | -12.3% | 2,219,762 | -12.0% | 0.00% | 0.0% |
| Q2 2022 | $7,362,000 | -59.8% | 2,521,333 | -2.7% | 0.00% | 0.0% |
| Q1 2022 | $18,316,000 | -55.5% | 2,590,722 | +0.8% | 0.00% | -66.7% |
| Q4 2021 | $41,125,000 | – | 2,570,270 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RiverVest Venture Management LLC | 1,441,444 | $10,191,000 | 10.46% |
| AJU IB Investment Co., Ltd. | 667,742 | $4,721,000 | 7.29% |
| Atlas Venture Life Science Advisors, LLC | 2,759,344 | $19,509,000 | 2.47% |
| Bain Capital Life Sciences Investors, LLC | 2,805,413 | $19,834,000 | 1.93% |
| Soleus Capital Management, L.P. | 477,495 | $3,376,000 | 0.44% |
| Monashee Investment Management LLC | 163,066 | $1,153,000 | 0.33% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,078,692 | $14,696,000 | 0.33% |
| RA Capital Management | 2,002,217 | $14,156,000 | 0.31% |
| HARVARD MANAGEMENT CO INC | 416,059 | $2,942,000 | 0.30% |
| Rock Springs Capital Management LP | 1,191,094 | $8,421,000 | 0.21% |